Tag Archives: consolidation
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter. (13:27)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice. (9:52)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups. (7:21)
Is Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025)
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still open questions of whether consolidation durvalumab (Imfinzi) in stage III unresectable NSCLC should be discontinued after a year. (6:32)
Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024)
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation. (7:43)